Personalized Medicine for Pulmonary Hypertension:

Pulmonary hypertension is a convergent phenotype that presents late in the natural history of condition. The current clinical classification patients lacks granularity, and this impacts on development deployment treatment. Deep molecular phenotyping using platform ‘omic’ technologies beginning to reveal genetic architecture underlies phenotype, promising better targeting with new treatments. future treatment pulmonary depends integration information create taxonomy defines patient groups coupled druggable targets.